Assessment of Interstitial Fluid Adenosine: Implications for Exogenous and Endogenous Adenosine-Mediated Cardioprotection

  • David G. L. Van Wylen
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 181)

Abstract

This chapter focuses on a specific aspect of the cardioprotective properties of adenosine, namely how the sampling of myocardial interstitial fluid (ISF) and the estimate of the changes in ISF adenosine provides insight into the protective actions of adenosine. As such, this chapter will concentrate on adenosine itself, both endogenously produced as well as exogenously administered, and will describe the effectiveness of certain pharmaceutical strategies designed to augment endogenous ISF adenosine. Because of the emphasis on the assessment of ISF adenosine, the wealth of important and interesting data dealing with pharmacological agents which are cardioprotective due to their direct actions at the adenosine receptor will not be discussed in this chapter.

Keywords

Ischemia Adenosine Cardiol Purine Nucleoside 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ely SW, Berne RM. Protective effects of adenosine in myocardial ischemia. Circulation 1992;85:893–902.PubMedGoogle Scholar
  2. 2.
    Belardinelli L, Linden J, Berne RM. The cardiac effects of adenosine. Prog Cardiovasc Dis 1989;32:73–97.PubMedCrossRefGoogle Scholar
  3. 3.
    Pelleg A, Bellardinelli L. Cardiac electrophysiology and pharmacology of adenosine: basic and clinical aspects. Cardiovasc Res 1993;27:54–61.PubMedCrossRefGoogle Scholar
  4. 4.
    Lawson CS, Downey JM. Preconditioning: State of the art myocardial protection. Cardiovasc Res 1993;27:542–550.PubMedCrossRefGoogle Scholar
  5. 5.
    Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124–1136.PubMedCrossRefGoogle Scholar
  6. 6.
    Forman MB, Velasco CE, Jackson EK. Adenosine attenuates reperfusion injury following regional myocardial ischemia. Cardiovasc Res 1993;27:9–17.PubMedCrossRefGoogle Scholar
  7. 7.
    Akiyama T, Yamazaki T, Nonomiya I. In vivo monitoring of myocardial interstitial norepinephrine by dialysis technique. Am J Physiol 1991;261:H1643–1647.PubMedGoogle Scholar
  8. 8.
    Decking UK, Juengling E, Kammermier H. Interstitial transudate concentration of adenosine and inosine in rat and guinea pig hearts. Am J Physiol 1988;254:H1125–1132.PubMedGoogle Scholar
  9. 9.
    Fenton RA, Dobson JG Jr. Measurement by fluorescence of interstitial fluid adenosine levels in normoxic, hypoxic, and ischemic perfused rat hearts. Circ Res 1987;60:177–184.PubMedGoogle Scholar
  10. 10.
    Gidday JM, Hill HE, Rubio R, Berne RM. Estimates of left ventricular interstitial fluid adenosine during catecholamine stimulation. Am J Physiol 1988;254:H207–216.PubMedGoogle Scholar
  11. 11.
    Hanley F, Messina LM, Baer RW, Uhlig PN, Hoffman JE. Direct measurement of left ventricular interstitial fluid adenosine. Am J Physiol 1983;245:H327–335.PubMedGoogle Scholar
  12. 12.
    Heller LJ, Mohrman DH. Estimates of interstitial fluid adenosine from surface exudates of isolated rat hearts. J Mol Cell Cardiol 1988;20:509–523.PubMedCrossRefGoogle Scholar
  13. 13.
    Imai S, Chin W, Jin H, Nakazawa M. Production of AMP and adenosine in the interstitial fluid compartment of the isolated perfused normoxic guinea pig heart. Pflugers Arch 1989;414:443–449.PubMedCrossRefGoogle Scholar
  14. 14.
    Kusachi S, Olsson RA. Pericardial superfusion to measure cardiac interstitial adenosine concentration. Am J Physiol 1983;244:H458–461.PubMedGoogle Scholar
  15. 15.
    Rubio R, Berne RM. Release of adenosine by the normal myocardium in dogs and its relationship to the regulation of coronary resistance. Circ Res 1969;25:407–415.PubMedGoogle Scholar
  16. 16.
    Tietjan CS, Tribble CG, Gidday JM, Phillips CL, Belardinelli L, Rubio R, Berne RM. Interstitial adenosine in guinea pig hearts: an index obtained by epicardial discs. Am J Physiol 1990;259:H147–M476.Google Scholar
  17. 17.
    Wangler RD, Gorman MW, Wang CY, DeWitt DF, Chan IS, Bassingthwaighte JB, Sparks HV. Transcapillary adenosine transport and interstitial adenosine concentration in guinea pig hearts. Am J Physiol 1989;257:H89–106.PubMedGoogle Scholar
  18. 18.
    Van Wylen DGL, Willis J, Sodhi J, Weiss RJ, Lasley RD, Mentzer RM Jr. Cardiac microdialysis to measure interstitial adenosine and coronary blood flow. Am J Physiol 1990;259:H1642–1648.Google Scholar
  19. 19.
    Van Wylen DGL, Schmit T, Lasley RD, Gingell RL, Mentzer RM Jr. Cardiac Microdialysis in isolated rat hearts: interstitial purine metabolites during ischemia. Am J Physiol 1992;262:H1934–1938.PubMedGoogle Scholar
  20. 20.
    Silva PH, Dillon D, Van Wylen DGL. Adenosine deaminase inhibition augments interstitial adenosine but does not attenuate myocardial infarction. Cardiovasc Res, 1995. (In press)Google Scholar
  21. 21.
    Dorheim T, Wang T, Mentzer RM Jr, Van Wylen DGL. Interstitial purine metabolites during regional myocardial ischemia. J Surg Res 1990;48:491–497.PubMedCrossRefGoogle Scholar
  22. 22.
    Delyani JA, Van Wylen DGL. Endocardial and epicardial interstitial purine metabolites and lactate during graded ischemia. Am J Physiol 1994;266:H1019–1026.PubMedGoogle Scholar
  23. 23.
    Van Wylen DGL. Effect of ischemic preconditioning on interstitial purine metabolite and lactate accumulation during myocardial ischemia. Circulation 1994;89:2283–2289.PubMedGoogle Scholar
  24. 24.
    Dorheim T, Hoffman A, Van Wylen DGL, Mentzer RM Jr. Enhanced interstitial fluid adenosine attenuates myocardial stunning. Surgery 1991;110:136–145.PubMedGoogle Scholar
  25. 25.
    Hudspeth DA, Williams MW, Zhao Z-Q, Sato H, Nakanishi K, McGee DS, Hammon JW Jr, Vinten-Johansen J, Van Wylen DGL. Pretreatment with pentostatin augments interstitial fluid adenosine and prevents post-ischemic dysfunction in canine hearts protected with blood cardioplegia. Ann Thorac Surg 1994;58:719–727.PubMedCrossRefGoogle Scholar
  26. 26.
    McClanahan TB, Ignasiak DP, Martin BJ, Mertz TE, Gallagher KP. Inhibition of adenosine deaminase with pentostatin attenuates myocardial stunning in dogs. Circulation 1993;88(Suppl I):I-187.Google Scholar
  27. 27.
    Wu S, Fu L, Koke JR, Bittar N. Contractility, ATP, and creatine phosphate during myocardial ischaemia and reperfusion: the effects of adenosine and inhibition of adenosine catabolism in the dog heart. Cytobios 1987;50:7–12.PubMedGoogle Scholar
  28. 28.
    Dhasmana JP, Digerness SB, Geckle JM, Ng TC, Glickson JD, Blackstone EH. Effect of adenosine deaminase inhibitors of the heart’s functional and biochemical recovery from ischemia: a study utilizing and isolated rat heart adapted to P nuclear magnetic resonance. J Cardiovasc Pharmacol 1983;5:1040–1047.PubMedCrossRefGoogle Scholar
  29. 29.
    Sandhu GS, Burrier AC, Janero DR. Adenosine deaminase inhibitors attenuate ischemic injury and preserve energy balance in isolated guinea pig heart. Am J Physiol 1993;265:H1249–1256.PubMedGoogle Scholar
  30. 30.
    Zhu Q, Chen S, Zou C. Protective effects of an adenosine deaminase inhibitor on ischemiareperfusion injury in isolated perfused rat heart. Am J Physiol 1990;259:H835–838.PubMedGoogle Scholar
  31. 31.
    Zhu Q, Yang X, Claydon MA, Hicks GL Jr, Wang T. Adenosine deaminase inhibitor in cardioplegia enhanced function preservation of the hypothermically stored rat heart. Transplantation 1994;57:35–40.PubMedCrossRefGoogle Scholar
  32. 32.
    Humphrey SM, Holliss DG, Cartner LA. Influence of inhibitors of ATP catabolism on myocardial recovery after ischemia. J Surg Res 1987;43:187–195.PubMedCrossRefGoogle Scholar
  33. 33.
    Li Y, Kloner RA Adenosine deaminase inhibition is not cardioprotective in the rat. Am Heart J 1993;126:1293–1298.PubMedCrossRefGoogle Scholar
  34. 34.
    Mullane K. Acadesine: the prototype adenosine regulating agent for reducing myocardial ischaemic injury. Cardiovasc Res 1993;27:43–47.PubMedCrossRefGoogle Scholar
  35. 35.
    Zhao Z, Williams MW, Sato H, Hudspeth DA, McGee BS, Vinten-Johansen J, Van Wylen DGL. Acadesine reduces myocardial infarct size by an adenosine-mediated Mechanism. Cardiovasc Res, 1995. (In press)Google Scholar
  36. 36.
    Van Belle H. Nucleoside transport inhibition: a therapeutic approach to cardioprotection via adenosine? Cardiovasc Res 1993;27:68–76.PubMedCrossRefGoogle Scholar
  37. 37.
    Wang T, Mentzer RM Jr, Van Wylen DGL. Interstitial adenosine with dipyridamole: effect of adenosine receptor blockade and adenosine deaminase. Am J Physiol 1992;263:H552–558.PubMedGoogle Scholar
  38. 38.
    Abd-Elfattah AS, Ding M, Dyke CM, Wechsler AS. Protection of the stunned myocardium: selective nucleoside transport blocker administered after 29 minutes of ischemia augments recovery of ventricular function. Circulation 1993;88(part 2):336–343.Google Scholar
  39. 39.
    Zughaib ME, Abd-Elfattah AS, Jeroudi MO, Sun J, Sekili S, Tang X, Bolli R. Augmentation of endogenous adenosine attenuates myocardial stunning independently of coronary flow or hemodynamic effects. Circulation 1993;88(part l):2359–2369.PubMedGoogle Scholar
  40. 40.
    Bruns RF, Fergus JH. Allosteric enhancement of adenosine At receptor binding and function by 2-amino-3-benzoylthiophenes. Mol Pharmacol 1990;38:939–949.PubMedGoogle Scholar
  41. 41.
    Mudumbi RV, Montamat SC, Bruns RF, Vestal RE. Cardiac functional responses of adenosine by PD 81,723, an allosteric enhancer of the adenosine A 1 receptor. Am J Physiol 1993;264:H1017–1022.PubMedGoogle Scholar
  42. 42.
    Miura T, Iimura O. Infarct size limitation by preconditioning: its phenomenological features and the key role of adenosine. Cardiovasc Res 1993;27:36–42.PubMedCrossRefGoogle Scholar
  43. 43.
    Kitakaze M, Hori M, Takashima S, Sato H, Inoue M, Kamada T. Ischemic preconditioning increases adenosine release and 5′-nucleotidase activity during myocardial ischemia and reperfusion in dogs: implications for myocardial salvage. Circulation 1993;87:208–215.PubMedGoogle Scholar
  44. 44.
    Murry CE, Richard VJ, Reimer KA, Jennings RB. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during a sustained ischemic episode. Circ Res 1990;66:913–931.PubMedGoogle Scholar
  45. 45.
    Nees S, Herzog V, Becker BF, Bock M, Des Rosiers CH, Gerlach E. The coronary endothelium: a highly effective barrier for adenosine. Basic Res Cardiol 1985;80:515–529.PubMedCrossRefGoogle Scholar
  46. 46.
    Kroll K, Schrader J, Piper HM, Henrich, H. Release of adenosine and cyclic AMP from coronary endothelium in isolated guinea pig hearts: relation to coronary flow. Circ Res 1987;60:659–665.PubMedGoogle Scholar
  47. 47.
    Van Wylen DGL. Relationship between intracoronary adenosine, interstitial fluid purine metabolites, and coronary blood flow. Drug Dev Res 1994;31:330.Google Scholar
  48. 48.
    Tsuchida A, Liu Y, Liu GS, Cohen MV, Downey JM. α 1-adrenergic agonists precondition rabbit ischemic myocardium independent of adenosine by direct activation of protein kinase C. Circ Res 1994;75:576–585.PubMedGoogle Scholar
  49. 49.
    Speechly-Dick ME, Mocanu MM, Yellon, DM. Protein kinase C: its role in ischemic preconditioning in the rat. Circ Res 1994;75:586–590.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • David G. L. Van Wylen
    • 1
  1. 1.Department of BiologySt. Olaf CollegeNorthfieldUSA

Personalised recommendations